print_label | resize_label

A TREATMENT FOR ADULTS WITH TYPE 2 DIABETES MELLITUS, IN ADDITION TO DIET AND EXERCISE

Demonstrated reductions in A1C levels with additional weight and blood pressure* benefits

FARXIGA is not indicated for weight loss or the treatment of hypertension.

*BP reductions when added to metformin.

BROAD RANGE OF CLINICAL RESULTS

INITIAL THERAPY WITH FARXIGA

 

FARXIGA 5 mg Initial Combination Therapy With Metformin XR

FARXIGA 5 mg in combination with metformin XR in treatment-naïve adults with type 2 diabetes mellitus

 

FARXIGA 10 mg Initial Combination Therapy With Metformin XR

FARXIGA 10 mg in combination with metformin XR in treatment-naïve adults with type 2 diabetes mellitus

 

FARXIGA 5 mg and 10 mg Initial Monotherapy

FARXIGA 5 mg and FARXIGA 10 mg as initial monotherapy in treatment-naïve adults with type 2 diabetes mellitus

Recommended starting dose is 5 mg.

FARXIGA AS ADD-ON THERAPY

 

FARXIGA as Add-On Therapy to Metformin

FARXIGA 5 mg and FARXIGA 10 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control with metformin

 

FARXIGA as Add-On Therapy to Sitagliptin (a DPP-4i)

FARXIGA 10 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control with sitagliptin with/without metformin

 

FARXIGA as Add-On Therapy to Glimepiride (a Sulfonylurea)

FARXIGA 5 mg and FARXIGA 10 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control with glimepiride

 

FARXIGA as Add-On Therapy to Pioglitazone (a Thiazolidinedione)

FARXIGA 5 mg and FARXIGA 10 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control on pioglitazone monotherapy

FARXIGA AS ADD-ON TO INSULIN

 

FARXIGA as Add-On to Insulin ± Oral Antidiabetic(s)

FARXIGA 5 mg and FARXIGA 10 mg in adults with type 2 diabetes mellitus receiving insulin

 

HEAD-TO-HEAD DATA WITH FARXIGA + METFORMIN

 

Head-to-Head vs Glipizide (a Sulfonylurea) + Metformin: 1-Year Data

FARXIGA 5 mg and FARXIGA 10 mg vs glipizide as add-on therapy in adults with type 2 diabetes mellitus who had inadequate glycemic control with metformin at 1 year

 

Head-to-Head vs Glipizide (a Sulfonylurea) + Metformin: 2- and 4-Year Data

FARXIGA 5 mg and FARXIGA 10 mg vs glipizide as add-on therapy in adults with type 2 diabetes mellitus who had inadequate glycemic control with metformin at 2 and 4 years

 

ADDITIONAL BENEFITS OF FARXIGA

 

Weight Reductions

FARXIGA 5 mg in combination with metformin XR in treatment-naïve adults with type 2 diabetes mellitus

 

Blood Pressure Reductions

FARXIGA 5 mg and FARXIGA 10 mg in adults with type 2 diabetes mellitus who had inadequate glycemic control with metformin

FARXIGA is not indicated for weight loss or the treatment of hypertension.

Change in A1C was evaluated as the primary end point. Weight and blood pressure reductions were secondary and additional end points.